Altre lingue Gain Therapeutics, Inc.

Azioni

GANX

US36269B1052

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 11/07/2024			Variaz. 5gg	Var. 1 gen.
1,36 ^USD	+13,33%		+17,24%	-58,35%

09/07	Gain Therapeutics, Inc. annuncia il completamento del dosaggio nella dose multipla ascendente (MAD) dello studio di Fase 1 di GT-02287, una innovativa terapia a piccole molecole per la malattia di Parkinson	CI
28/06	Aggiornamento settoriale: titoli del settore sanitario in rialzo prima della campanella di venerdì	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson's disease	10/07
Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson’s Disease	09/07
Gain Therapeutics, Inc. Announces the Completion of Dosing in the Multiple Ascending Dose of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson?s Disease	09/07
Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024	28/06
Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024	28/06
Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson's disease	28/06
Sector Update: Health Care Stocks Higher Pre-Bell Friday	28/06
Gain Therapeutics Names Gene Mack as Interim Chief Executive Officer	27/06
Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO	27/06
Gain Therapeutics, Inc. Announces CEO Changes	27/06
Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease	27/06
Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference	25/06
Sector Update: Health Care Stocks Softer Friday Afternoon	14/06
Top Midday Decliners	14/06
Gain Therapeutics Shares Tumble After Company Prices $11.0 Million Public Offering	14/06
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday as Investors Eye Fed Policy Easing	14/06
Top Premarket Decliners	14/06
Gain Therapeutics Announces Pricing of $11.0 Million Public Offering	14/06
Gain Therapeutics Plans Common Stock Offering to Finance Treatment for Neurodegenerative Disorders; Shares Fall After Hours	13/06
Gain Therapeutics Announces Proposed Public Offering	13/06

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Gain Therapeutics, Inc.

Azioni

GANX

US36269B1052

Altre lingue

Filtri